Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.48 USD
169.74 M USD
7.80 B USD
257.30 M
About Grifols, S.A. Class A
Sector
Industry
CEO
Jose Ignacio Abia Buenache
Website
Headquarters
Barcelona
Founded
1940
ISIN
US3984384087
FIGI
BBG001QMCKF6
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
GRFS5271380
Grifols Escrow Issuer SA 4.75% 15-OCT-2028Yield to maturity
5.95%
Maturity date
Oct 15, 2028
XS239300189
Grifols Escrow Issuer SA 3.875% 15-OCT-2028Yield to maturity
4.72%
Maturity date
Oct 15, 2028
XS207764639
Grifols, S.A. 2.25% 15-NOV-2027Yield to maturity
3.24%
Maturity date
Nov 15, 2027
See all GRFS bonds